secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001104659-23-080576
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx reports ELX-02 Phase 2 data: partial remission in 1 of 3 Alport patients
------------------------------------------------------------------------------

- Patient 4401-02 showed ~49% average reduction in UPCR (p=0.009) after 8 weeks of ELX-02.
- Two other patients (4401-01, 4402-01) had no meaningful change in proteinuria.
- All three patients had COL4A4 nonsense mutations and background RAAS blockade.
- Patient 4401-02's remission rebounded 1 month after treatment withdrawal.
- Results from KOL Day on June 27, 2023 disclosed via 8-K filed July 13.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923080576/0001104659-23-080576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923080576/tm2321215d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-080576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer